Why Amarin Shares Dropped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of cardiovascular-focused biotechnology company Amarin (Nasdaq: AMRN  ) dipped as much as 13% earlier in the trading session after more question marks were raised regarding the marketing exclusivity of Vascepa, its FDA-approved triglyceride reducing drug that, when used in combination with proper diet and exercise, can reduce the risk of heart attack and/or stroke.

So what: In an 8-K released this morning, Amarin noted that it's still awaiting word from the FDA regarding the new chemical entity, or NCE, status of Vascepa. At stake for Amarin is whether or not Vascepa will receive marketing exclusivity for a length of five years. As with all drugs, exclusivity is expected, but not necessarily always granted by the FDA, and that's the primary cause for today's drop.

Now what: I wouldn't completely overreact based on today's 8-K filing if I were an Amarin shareholder, as a delay in an NCE ruling isn't completely uncommon -- but admittedly, shareholders are starting to sweat. The key point here is that Amarin remains a prime takeover target in the biotech sector, and, assuming it finds a solid marketing partner (and trust me, there's no shortage of big pharmaceutical companies with declining pipelines that'd love to get their hands on Vascepa's revenue stream), the long-term future for Amarin remains bright.

Craving more input? Start by adding Amarin to your free and personalized Watchlist so you can keep up on the latest news with the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2052325, ~/Articles/ArticleHandler.aspx, 8/23/2014 5:47:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASD 4,538.55 6.45 0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/22/2014 3:59 PM
AMRN $1.83 Up +0.04 +2.23%
Amarin Corp plc (A… CAPS Rating: ***

Advertisement